gip/glp 1-agonist tirzepatide Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Tirzepatide Research Peptide | cGMP

Dahl D, et al

For this analysis, individual patient data were also utilized from the SURPASS2 study because of existing differences between the two studies (as described below)

Tirzepatide represents a significant advancement in diabetes treatment, offering benefits beyond traditional medications

Consider an auto-injector device if manual syringe injection is too anxiety-provoking

The triple agonist mechanism appears to match or slightly exceed tirzepatide for blood sugar management , likely because the glucagon component, while it can raise blood sugar in isolation, works synergistically with GLP-1 and GIP activation to produce a net positive effect on glucose regulation

If you notice signs of dehydrationdark urine, persistent dry mouth, dizziness, or headachesincrease water intake by 1015 ounces daily and monitor for improvement over 2448 hours